Prof. Alan Talevi (PhD)
Drug discovery and development Scientist
Prof Alan Talevi (PhD)
Drug discovery and development Scientist
Prof Dr Alan Talevi is a Pharmacist with expertise in the fields of Medicinal Chemistry, Drug Discovery and Development, and Pharmacokinetics. He writes and reviews content related to Pharmacology and Pharmacokinetics.
Dr Alan Talevi’s Highlights:
Researcher at the Argentinean Council of Scientific and Technical Research (CONICET). Full Professor of Biopharmacy at the University of La Plata.
PhD in Exact Sciences with a focus on Medicinal Chemistry at the University of La Plata/ Argentina. Pharmacist and Bachelor in Pharmacy at the University of La Plata/ Argentina.
Professional Experience:
After obtaining his PhD, Dr Alan Talevi obtained a permanent position at the Argentinean National Council of Scientific and Technical Research (CONICET). He has taught courses on the Pharmacy career at the University of La Plata for more than 20 years,
Dr Alan Talevi has acted as PI in more than 10 national and international scientific grants.
Dr Alan Talevi has also acted as an external reviewer for several agencies, universities and organizations from the UK, Belgium, Poland, Argentina, Uruguay, Chile, Perú and Brazil. He is a member of the editorial board of several journals: Editorial Board Member of Current Therapeutic Research (Elsevier) and the Latin American Journal of Pharmacy, Reviewing Editor for eLife, and Associate Editor for Frontier in Natural Products. He has edited several books, including the ADME Encyclopedia (Springer Nature’s Major Reference Works series).
Dr Alan Talevi participated as a member of the examination board for more than 20 Ph.D. exams at several universities, including the University of La Plata, the University of Buenos Aires, the University of Rosario, the University of San Martín, the University of Quilmes, and Rhodes University. He has supervised 6 approved PhD thesis.
Education:
2004 Bachelor in Pharmacy at the University of La Plata, Argentina
2007 PhD in Exact Sciences at the University of La Plata, Argentina
2023 Bachelor in Creative Writing at the National University of Arts, Argentina
The main recent publications of Dr. Alan Talevi (among more than 100) are:
| 1. | Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects.
Talevi A. Methods Mol Biol. 2024;2714:1-20. |
| 2. | Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies.
Muraca G, Ruiz ME, Gambaro RC, Scioli-Montoto S, Sbaraglini ML, Padula G, Cisneros JS, Chain CY, Álvarez VA, Huck-Iriart C, Castro GR, Piñero MB, Marchetto MI, Alba Soto C, Islan GA, Talevi A. Beilstein J Nanotechnol. 2023 Jul 28;14:804-818. |
| 3. | Synthesis and biological evaluation of new antiseizure compounds derived from valproic acid.
Garofalo FM, Sbaraglini ML, Barrionuevo EM, Peralta E, Bonifazi EL, Talevi A, Gavernet L. Future Med Chem. 2023 May;15(9):735-743. |
| 4. | Making the most effective use of available computational methods for drug repositioning.
Prada Gori DN, Alberca LN, Talevi A. Expert Opin Drug Discov. 2023 May;18(5):495-503. |
| 5. | A combined ligand and target-based virtual screening strategy to repurpose drugs as putrescine uptake inhibitors with trypanocidal activity.
Llanos MA, Alberca LN, Ruiz MD, Sbaraglini ML, Miranda C, Pino-Martinez A, Fraccaroli L, Carrillo C, Alba Soto CD, Gavernet L, Talevi A. J Comput Aided Mol Des. 2023 Feb;37(2):75-90. |
| 6. | Identification of New Carbonic Anhydrase VII Inhibitors by Structure-Based Virtual Screening.
Gantner ME, Prada Gori DN, Llanos MA, Talevi A, Angeli A, Vullo D, Supuran CT, Gavernet L. J Chem Inf Model. 2022 Oct 10;62(19):4760-4770. |
| 7. | Novel Phenobarbital-Loaded Nanostructured Lipid Carriers for Epilepsy Treatment: From QbD to In Vivo Evaluation.
Scioli-Montoto S, Sbaraglini ML, Cisneros JS, Chain CY, Ferretti V, León IE, Alvarez VA, Castro GR, Islan GA, Talevi A, Ruiz ME. Front Chem. 2022 Aug 17;10:908386. |
| 8. | Structure-Based Virtual Screening Identifies Novobiocin, Montelukast, and Cinnarizine as TRPV1 Modulators with Anticonvulsant Activity In Vivo.
Llanos MA, Enrique N, Sbaraglini ML, Garofalo FM, Talevi A, Gavernet L, Martín P. J Chem Inf Model. 2022 Jun 27;62(12):3008-3022. |
| 9. | Antiseizure medication discovery: Recent and future paradigm shifts.
Talevi A. Epilepsia Open. 2022 Aug;7 Suppl 1(Suppl 1):S133-S141. |
| 10. | Tetracycline Derivatives Inhibit Plasmodial Cysteine Protease Falcipain-2 through Binding to a Distal Allosteric Site.
Hernández González JE, Alberca LN, Masforrol González Y, Reyes Acosta O, Talevi A, Salas-Sarduy E. J Chem Inf Model. 2022 Jan 10;62(1):159-175. |
| 11. | Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study.
Llanos MA, Gantner ME, Rodriguez S, Alberca LN, Bellera CL, Talevi A, Gavernet L. J Chem Inf Model. 2021 Aug 23;61(8):3758-3770. |
| 12. | Can drug repurposing strategies be the solution to the COVID-19 crisis?
Bellera CL, Llanos M, Gantner ME, Rodriguez S, Gavernet L, Comini M, Talevi A. Expert Opin Drug Discov. 2021 Jun;16(6):605-612. |
| 13. | Parabens inhibit hNaV 1.2 channels.
Enrique A, Martín P, Sbaraglini ML, Talevi A, Milesi V. Biomed Pharmacother. 2020 Aug;128:110250. |
| 14. | Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions.
Auzmendi J, Palestro P, Blachman A, Gavernet L, Merelli A, Talevi A, Calabrese GC, Ramos AJ, Lazarowski A. Front Behav Neurosci. 2020 Mar 17;14:32 . |
| 15. | Machine Learning in Drug Discovery and Development Part 1: A Primer.
Talevi A, Morales JF, Hather G, Podichetty JT, Kim S, Bloomingdale PC, Kim S, Burton J, Brown JD, Winterstein AG, Schmidt S, White JK, Conrado DJ. CPT Pharmacometrics Syst Pharmacol. 2020 Mar;9(3):129-142. |
| 16. | Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics.
Talevi A, Bellera CL. Expert Opin Drug Discov. 2020 Apr;15(4):397-401. |
| 17. | Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
Sbaraglini ML, Bellera CL, Quarroz Braghini J, Areco Y, Miranda C, Carrillo C, Kelly J, Buchholz B, Gelpi RJ, Talevi A, Alba Soto CD. Eur J Med Chem. 2019 Dec 15;184:111778. |
You can view some of his work below and links to his professional profile.
Researchgate: https://www.researchgate.net/profile/Alan-Talevi
Google Scholar: https://scholar.google.co.in/citations?user=TqFfWCsAAAAJ&hl=en
Scopus: https://www.scopus.com/authid/detail.uri?authorId=14833640500
Linkedin: https://www.linkedin.com/in/alan-talevi-8073571a/
